Halt Medical Introduces Team To Commercialize Acessa™ System For The Treatment Of Uterine Fibroids

Halt Medical Introduces Team To Commercialize Acessa™ System For The Treatment
                             Of Uterine Fibroids

PR Newswire

LIVERMORE, Calif., Jan. 9, 2013

LIVERMORE, Calif., Jan. 9, 2013 /PRNewswire/ --Halt Medical, Inc. introduced
today a team to drive commercialization of the Acessa System, a newly FDA
cleared medical device to treat uterine fibroids.

"It gives me great pleasure to introduce Rodney Marcy as our Senior Vice
President of Sales and Marketing," said Jeffrey Cohen, Halt's Chief Executive
Officer. "Rodney has extensive commercial experience in the medical device
field, and women's health sector. This will be instrumental in our successful
launch of Acessa."

Most recently, Mr. Marcy was Vice President of Sales and Marketing for
venture-funded Interlace Medical, Inc. (acquired by Hologic, Inc.). He was
alsoDirector of Sales for the launch of the Gynecare Division of ETHICON,
Inc., successfully introducing more than five major platform technologies in
women's health. He has held senior management positions with Johnson and
Johnson and Covidien.

"Acessa is the only medical device that can be used by gynecologists to treat
all fibroid symptoms and types," said Mr. Marcy. "It is truly a revolutionary
alternative for the millions of women with fibroids who choose to suffer with
their symptoms rather than having their uterus removed. Our launch of Acessa
will be led by three talented Regional Sales Directors: Larry Anderson, Tyler
Holcomb, and Mike Roddick."

Russ DeLonzor, President & COO, added, "We will need to support our customers
in the critical areas of reimbursement and professional education. I'm
delighted to announce the following additions to the Halt Medical team: Jayne
A. Little, Vice President of Global Health Economics and Reimbursement, and
Nonni Letasse, R.N., Senior Director of Professional Education and Corporate
Compliance."

Ms. Little was, most recently, the Vice President of Reimbursement at Optonol,
Inc. (acquired by Alcon, Inc.). Ms. Little has been responsible for AMA CPT
code implementation, Medicare and commercial payer coverage and policy.
Joining Ms. Little's team is Sean McKinney, Region Director, Reimbursement and
Healthcare Economics.

Ms. Letasse was Senior Director, Global Professional Education for Conceptus,
Inc. She has over twenty years of training experience in the women's health
sector. She has selected Michelle Schwinges, Professional Education
Specialist, to round out her group.

Jeffrey Cohen added, "We now have FDA clearance, the capital, the product, and
the team to successfully launch Acessa."

About Halt Medical, Inc.

Founded in 2004, Halt Medical is a medical device company focused on
establishing a new standard of care for women with symptomatic uterine
fibroids. The Company has developed and launched the Acessa System and
Procedure, using radiofrequency energy to destroy uterine fibroids. The
results of both U.S. and international trials have led to the clearance of the
product by the FDA for use in percutaneous, laparoscopic coagulation and
ablation of soft tissue, including treatment of symptomatic uterine fibroids
under laparoscopic ultrasound guidance. As well, the System has CE marking in
the European Union and is licensed for sale in Canada. The Company is located
in Brentwood, CA. For information about the Acessa System, please visit
www.haltmedical.com.

SOURCE Halt Medical, Inc.

Website: http://www.haltmedical.com
Contact: Jeffrey M. Cohen, Chief Executive Officer, jeffcohen@haltmedical.com
 
Press spacebar to pause and continue. Press esc to stop.